News | July 22, 2025
AstraZeneca plans to invest $50 billion in US by 2030
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
The new Zigly center features and offers comprehensive veterinary services
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content
Commercial production is expected to begin soon
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
Subscribe To Our Newsletter & Stay Updated
